[go: up one dir, main page]

SK14322002A3 - Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin - Google Patents

Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin Download PDF

Info

Publication number
SK14322002A3
SK14322002A3 SK1432-2002A SK14322002A SK14322002A3 SK 14322002 A3 SK14322002 A3 SK 14322002A3 SK 14322002 A SK14322002 A SK 14322002A SK 14322002 A3 SK14322002 A3 SK 14322002A3
Authority
SK
Slovakia
Prior art keywords
percyquinnin
pharmaceutically acceptable
acid
compound
dsm
Prior art date
Application number
SK1432-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Cordula Hopmann
Michael Kurz
Guenter Mueller
Luigi Toti
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of SK14322002A3 publication Critical patent/SK14322002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1432-2002A 2000-04-07 2001-03-24 Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin SK14322002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107536A EP1142886A1 (en) 2000-04-07 2000-04-07 Percyquinnin, a process for its production and its use as a pharmaceutical
PCT/EP2001/003392 WO2001077094A1 (en) 2000-04-07 2001-03-24 Percyquinnin, a process for its production and its use as a pharmaceutical

Publications (1)

Publication Number Publication Date
SK14322002A3 true SK14322002A3 (sk) 2003-05-02

Family

ID=8168397

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1432-2002A SK14322002A3 (sk) 2000-04-07 2001-03-24 Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin

Country Status (30)

Country Link
US (1) US6596518B2 (ru)
EP (2) EP1142886A1 (ru)
JP (1) JP2003530391A (ru)
KR (1) KR100791798B1 (ru)
CN (1) CN1199959C (ru)
AT (1) ATE269855T1 (ru)
AU (2) AU784902B2 (ru)
BR (1) BR0109854A (ru)
CA (1) CA2405066A1 (ru)
CZ (1) CZ20023310A3 (ru)
DE (1) DE60103995T2 (ru)
DK (1) DK1274698T3 (ru)
EE (1) EE200200572A (ru)
ES (1) ES2222992T3 (ru)
HK (1) HK1052005A1 (ru)
HR (1) HRP20020796A2 (ru)
HU (1) HUP0300327A3 (ru)
IL (2) IL152073A0 (ru)
MX (1) MXPA02007895A (ru)
NO (1) NO20024772D0 (ru)
NZ (1) NZ521782A (ru)
PL (1) PL357909A1 (ru)
PT (1) PT1274698E (ru)
RS (1) RS50140B (ru)
RU (1) RU2266290C2 (ru)
SI (1) SI1274698T1 (ru)
SK (1) SK14322002A3 (ru)
TR (1) TR200401739T4 (ru)
WO (1) WO2001077094A1 (ru)
ZA (1) ZA200207910B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142886A1 (en) * 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Percyquinnin, a process for its production and its use as a pharmaceutical
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4765627B2 (ja) 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
US7572783B2 (en) 2004-08-13 2009-08-11 Amgen Inc. Substituted benzofused heterocycles
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
AU2006288153A1 (en) 2005-09-07 2007-03-15 Msd K.K. Bicyclic aromatic substituted pyridone derivative
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
US20080255084A1 (en) 2005-10-21 2008-10-16 Randy Lee Webb Combination of Organic Compounds
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
MY146564A (en) 2005-11-10 2012-08-30 Msd Kk Aza-substituted spiro derivatives
CN100417650C (zh) * 2006-08-17 2008-09-10 中国科学院昆明植物研究所 韧革菌素及其制备方法和在药物上的应用
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
EP2145884B1 (en) 2007-04-02 2014-08-06 Msd K.K. Indoledione derivative
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009220605A1 (en) 2008-03-06 2009-09-11 Msd K.K. Alkylaminopyridine derivative
CA2717384A1 (en) 2008-03-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
ES2981866T3 (es) 2013-06-05 2024-10-10 Bausch Health Ireland Ltd Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3186242B1 (en) 2014-08-29 2021-10-06 Tes Pharma S.r.l. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CN105906500B (zh) * 2016-04-22 2018-06-26 中国科学院昆明植物研究所 具有脂肪酶抑制作用的绵马次酸类化合物及其应用
BR112019007543A2 (pt) 2016-10-14 2019-07-02 Tes Pharma S R L inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN109055231B (zh) * 2018-07-26 2021-04-27 云南大学 一种真菌发酵液及其应用
SG11202104550WA (en) 2018-11-20 2021-05-28 Tes Pharma S R L INHIBITORS OF a-AMINO-ß-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
TW202045476A (zh) 2019-02-13 2020-12-16 美商默沙東藥廠 5-烷基吡咯啶食慾素受體促效劑
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
MX2023001840A (es) 2020-08-18 2023-03-13 Merck Sharp & Dohme Llc Agonistas de bicicloheptano pirrolidina de los receptores de orexina.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2344285A1 (fr) * 1976-03-19 1977-10-14 Roussel Uclaf Nouvelles lactones derivees du cyclopentanol, leur procede de preparation et leur application comme medicaments
US5322779A (en) * 1992-04-16 1994-06-21 The Research And Development Institute, Inc. At Montana State University Taxol production by taxomyces andreanae
EP1142886A1 (en) * 2000-04-07 2001-10-10 Aventis Pharma Deutschland GmbH Percyquinnin, a process for its production and its use as a pharmaceutical

Also Published As

Publication number Publication date
SI1274698T1 (en) 2004-12-31
BR0109854A (pt) 2003-06-03
KR20020084299A (ko) 2002-11-04
EP1142886A1 (en) 2001-10-10
DE60103995T2 (de) 2005-01-05
IL152073A (en) 2007-12-03
HUP0300327A2 (hu) 2003-06-28
HK1052005A1 (en) 2003-08-29
AU784902B2 (en) 2006-07-20
PL357909A1 (en) 2004-08-09
US20020039768A1 (en) 2002-04-04
HRP20020796A2 (en) 2004-12-31
MXPA02007895A (es) 2002-11-29
RU2266290C2 (ru) 2005-12-20
ES2222992T3 (es) 2005-02-16
AU2006203704B8 (en) 2008-07-10
CN1199959C (zh) 2005-05-04
EE200200572A (et) 2004-04-15
KR100791798B1 (ko) 2008-01-04
ATE269855T1 (de) 2004-07-15
AU5621901A (en) 2001-10-23
NO20024772L (no) 2002-10-03
NO20024772D0 (no) 2002-10-03
RU2002129890A (ru) 2004-03-27
AU2006203704A1 (en) 2006-09-21
RS50140B (sr) 2009-03-25
JP2003530391A (ja) 2003-10-14
AU2006203704B2 (en) 2008-06-26
TR200401739T4 (tr) 2004-08-23
DK1274698T3 (da) 2004-11-01
PT1274698E (pt) 2004-10-29
NZ521782A (en) 2004-05-28
ZA200207910B (en) 2003-07-21
US6596518B2 (en) 2003-07-22
WO2001077094A1 (en) 2001-10-18
EP1274698A1 (en) 2003-01-15
YU74002A (sh) 2005-11-28
CN1418203A (zh) 2003-05-14
EP1274698B1 (en) 2004-06-23
CA2405066A1 (en) 2001-10-18
IL152073A0 (en) 2003-05-29
DE60103995D1 (de) 2004-07-29
CZ20023310A3 (cs) 2003-01-15
HUP0300327A3 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
SK14322002A3 (sk) Percyquinnin, spôsob jeho prípravy, organizmus na tento spôsob a farmaceutická kompozícia obsahujúca Percyquinnin
US6673834B2 (en) Hydroperylene derivatives
AU750509B2 (en) Mumbaistatin, a process for its production and its use as a pharmaceutical
IL152612A (en) Cyclipostins, a method for their preparation, and their use
AU2002250997B2 (en) Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of CNS disorders and a process for the preparation thereof
EP3937931B1 (en) Macrocycles with antioxidant and neuroprotective activities
AU2002358015A1 (en) Hydroperylene derivatives
MXPA00011165A (es) Mumbaistatin, un proceso para su produccion y su empleo como un producto farmaceutico